Skip to content

Martin Tolar, M.D., Ph.D.

President and Chief Executive Officer at Alzheon.

Raised on Alzheon filings

$126.3M

of $150M offered across 1 Form D filing

Form D filings
1
Teammates
1
Last filing
Feb 10, 2025

Company

Alzheon

Biotech · Framingham, MA

Oral Alzheimer's drug targeting amyloid oligomers

Investors
76
Still open
$23.7M

Alzheon filings

  • EquityFiled Feb 10, 2025Form D/A
    $126.3M/ $150M

Works with